Fate Therapeutics Inc

Stock is in a Stage 2 uptrend medium-term bullish environment, showing a pullback into rising EMAs that have held support, offering a timely buy opportunity despite a Bullish Exhaustion pattern that signals possible short-term fatigue.

• ↑RECLAIM-LN Phase 2 trial for FT819 in SLE launched; first patient dosed.
• ↑$153.8M cash as of June 30 2026 funds operations into 2028.
• ↓Q2 2026 net loss $30M and EPS –$0.25 reflect ongoing losses.